On July 30, Gilead Sciences fell 3.02% in regular trading, trading at $129.14/share, with turnover of $196 million. The decline came as the broader biotechnology sector experienced significant selling pressure, compounded by short-term profit-taking following a 6%-plus rally over the prior two sessions.

The biotech sector saw widespread losses on the day, with Alnylam Pharmaceuticals plunging 26.48%, Madrigal Pharmaceuticals dropping 11.9%, AbbVie declining 2.84%, and Amgen falling 1.89%, reflecting pronounced sector-wide linkage effects. Gilead had previously rallied on optimism ahead of its August 4 earnings release and continued momentum from Trodelvy pipeline catalysts, including EMA CHMP recommendation for the Trodelvy-Keytruda combination in PD-L1 positive first-line metastatic triple-negative breast cancer. The sharp prior gains created conditions for technical profit-taking once the sector turned lower.

Additionally, Barclays recently reduced its price target on Gilead from $155 to $145 while maintaining an equalweight rating, adding incremental pressure on sentiment. The FactSet consensus mean target remains at $159.04 with an average overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)